Tamoxifen Added to Adjuvant Chemotherapy in Premenopausal Women with Early Breast Cancer: is it Standard Practice or Still a Subject for Study?

By Bramwell V.H.C.   Pritchard K.I.  

European Journal of Cancer, Vol. 35, Iss. 12, 1999-11 ,pp. : 1625-1627

Elsevier

Access to resources Recommend Favorite

Possible Deleterious Effect of Tamoxifen in Premenopausal Women with Locoregional Recurrence of Breast Cancer

By Borner M.M.   Bacchi M.   Castiglione M.  

European Journal of Cancer, Vol. 32, Iss. 12, 1996-11 ,pp. : 2173-2176

Elsevier

Access to resources Recommend Favorite

Adjuvant!^© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer

By Paridaens Robert   Gelber Shari   Cole Bernard   Gelber Richard   Thürlimann Beat   Price Karen   Holmberg Stig   Crivellari Diana   Coates Alan   Goldhirsch Aron  

Breast Cancer Research and Treatment, Vol. 123, Iss. 1, 2010-08 ,pp. : 303-310

Springer Publishing Company

Access to resources Recommend Favorite

Ovarian Overstimulation and Cystic Formation in Premenopausal Tamoxifen Exposure: Comparison between Tamoxifen-Treated and Nontreated Breast Cancer Patients

By Cohen I.   Figer A.   Tepper R.   Shapira J.   Altaras M.M.   Yigael D.   Beyth Y.  

Gynecologic Oncology, Vol. 72, Iss. 2, 1999-02 ,pp. : 202-207

Elsevier

Access to resources Recommend Favorite

Tamoxifen in High-risk Premenopausal Women with Primary Breast Cancer Receiving Adjuvant Chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B Trial

By Andersson M.   Kamby C.   Jensen M.-B.   Mouridsen H.   Ejlertsen B.   Dombernowsky P.   Rose C.   Cold S.   Overgaard M.   Andersen J.   Kjaer M.  

European Journal of Cancer, Vol. 35, Iss. 12, 1999-11 ,pp. : 1659-1666

Elsevier

Access to resources Recommend Favorite